Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valiloxybate for Excessive Daytime Sleepiness in Parkinson's Disease
NCT05056194Phase 2Withdrawn
- Sponsor
- XWPharma
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Excessive Daytime Sleepiness (EDS) comparing Valiloxybate with Placebo (2 arms). Primary endpoint: Epworth Sleepiness Scale at 6 weeks. Planned start Nov 2021; status: withdrawn.
02
Drugs
valiloxybate
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on NCT05056194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056194.